Business Description
Dyne Therapeutics Inc
NAICS : 541714
SIC : 2833
1560 Trapelo Road, Waltham, MA, USA, 02451
Description
Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.86 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.21 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -84.5 | |||||
| 3-Year EPS without NRI Growth Rate | -84.6 | |||||
| 3-Year FCF Growth Rate | -79.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.63 | |||||
| 9-Day RSI | 67.75 | |||||
| 14-Day RSI | 67.34 | |||||
| 6-1 Month Momentum % | 26.16 | |||||
| 12-1 Month Momentum % | -55.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.82 | |||||
| Quick Ratio | 14.82 | |||||
| Cash Ratio | 13.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -70.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -39.01 | |||||
| ROA % | -35.71 | |||||
| ROIC % | -487.93 | |||||
| ROC (Joel Greenblatt) % | -565.7 | |||||
| ROCE % | -37.48 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.76 | |||||
| Price-to-Tangible-Book | 1.76 | |||||
| EV-to-EBIT | -1.89 | |||||
| EV-to-EBITDA | -1.9 | |||||
| EV-to-FCF | -1.92 | |||||
| Price-to-Net-Current-Asset-Value | 2.01 | |||||
| Price-to-Net-Cash | 2.17 | |||||
| Earnings Yield (Greenblatt) % | -52.91 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:DYN
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -3.1 | ||
| Beta | 0 | ||
| Volatility % | 97.57 | ||
| 14-Day RSI | 67.34 | ||
| 14-Day ATR ($) | 0.819485 | ||
| 20-Day SMA ($) | 10.477 | ||
| 12-1 Month Momentum % | -55.3 | ||
| 52-Week Range ($) | 4.3 - 19.74 | ||
| Shares Outstanding (Mil) | 51.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dyne Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||